Acadia Pharmaceuticals target price cut to $31 from $38
ACAD•Deutsche Bank cut its target price for Acadia Pharmaceuticals to $31 from $38.
Related News
Atlas Energy Solutions announces equipment purchase agreements backed by cost reimbursement agreements with a leading frontier AI lab
AESI•
Core Scientific appoints Jay Elms chief commercial officer
CORZ•
U.S. FDA approves Welireg plus Lenvima for certain previously treated adults with advanced renal cell carcinoma
MRK•
Jury finds Lilly breaches implied covenant in rezpegaldesleukin license, awards Nektar $90 million plus interest
NKTR•
Cipher Digital extends Barber Lake data center lease to 20 years, lifts contracted revenue to over $9 billion
CIFR•